2019-nCoV: A wake-up call
Outbreaks like 2019-nCoV underline the need for more R&D investment in infectious diseases
Author
Will Budget 2020 be a salve or a sting for India Pharma Inc?
Will the sector get their shocks post-budget, via a revamped UCPMP, further pricing woes, etc?
Why API price needs to be part of NPPA’s pricing formula
The over-dependence on China and other countries imperils not just the health of the pharma industry in India, but also that of…
UK’s NHS post Brexit: Get updated!
Lord David Prior of Brampton, Chairman, National Health Service England & University College Hospital in conversation with…
SCHOTT Glass strenghtens India facility as Asian hub
With investments of close to €47 million in India over two years, global pharmaceutical glass manufacturer SCHOTT AG clearly sees…
“Patient-centric marketing will become a fundamental pillar in the future of pharma marketing”
Sumita Mohapatro Pani, Senior General Manager, Lupin speaks to Viveka Roychowdhury on the rewriting of the pharma sales and…
Will regulators catch up in 2020?
The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?
Rationalising pharma trade margins seems next on the list
Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…
Sustainable manufacturing practices to combat growing AMR
With antibiotic residues from effluents listed as the third highest cause of Antimicrobial Resistance (AMR), pharmaceutical…
Lupin sells stakes in Kyowa but its not a Sayonara
With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…